Pfizer (NYSE:PFE) Sees Strong Trading Volume

Shares of Pfizer Inc. (NYSE:PFE) saw strong trading volume on Monday . 15,044,100 shares were traded during trading, a decline of 62% from the previous session’s volume of 39,689,785 shares.The stock last traded at $29.69 and had previously closed at $29.97.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, July 10th. Finally, Barclays upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 10th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $34.50.

Pfizer Stock Down 1.1 %

The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a market cap of $167.90 billion, a P/E ratio of -494.92, a PEG ratio of 1.17 and a beta of 0.69. The company’s 50 day simple moving average is $28.40 and its 200-day simple moving average is $27.73.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.23 EPS. Research analysts forecast that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.67%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Hedge Funds Weigh In On Pfizer

Several institutional investors have recently made changes to their positions in the business. Olistico Wealth LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $25,000. Creekmur Asset Management LLC bought a new stake in Pfizer during the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC raised its stake in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Tennessee Valley Asset Management Partners bought a new stake in Pfizer during the 4th quarter worth approximately $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new stake in Pfizer during the 4th quarter worth approximately $37,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.